{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:29:45Z","timestamp":1785216585533,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Major depressive disorder (MDD) imposes a substantial burden worldwide, with treatment\u2010resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI) representing two of the most severe clinical challenges. Conventional antidepressants often require several weeks to exert benefit, leaving patients symptomatic and at risk during this delay. Esketamine nasal spray was the first glutamate\u2010modulating antidepressant to enter clinical practice and was recently approved as the first and only monotherapy for adults with TRD. Administered at 56\u2009mg or 84\u2009mg, esketamine offers a rapid onset of action. Intranasal delivery yields approximately 50% bioavailability and peak concentrations within 20\u201340\u2009min, correlating with early clinical effects. N\u2010methyl\u2010D\u2010aspartate (NMDA) receptor antagonism on inhibitory interneurons disinhibits glutamate release and modulates downstream synaptic plasticity pathways, providing a mechanistic basis for the rapid antidepressant effects of esketamine. This review summarizes the regulatory approval, mechanism of action, and pharmacokinetic\/pharmacodynamic characteristics, together with key clinical trial efficacy and safety data for esketamine nasal spray in TRD and MDSI.<\/jats:p>","DOI":"10.1111\/cts.70527","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:24:09Z","timestamp":1775111049000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-8797","authenticated-orcid":false,"given":"Matthijs W.","family":"van Hoogdalem","sequence":"first","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-0743","authenticated-orcid":false,"given":"Dong\u2010Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-3930","authenticated-orcid":false,"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-3862","authenticated-orcid":false,"given":"Peter N.","family":"Zannikos","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"issue":"8","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3171","article-title":"Suicide\u2010Specific Mortality Among Patients With Treatment\u2010Resistant Major Depressive Disorder, Major Depressive Disorder With Prior Suicidal Ideation or Suicide Attempts, or Major Depressive Disorder Alone","volume":"13","author":"Kern D. M.","year":"2023","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300341"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/313479a0"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1903305"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mhw.32471"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l7069"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.023"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy094"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.09.030"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0733-19.2019"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3634"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00612"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620937899"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat8078"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-02021-1"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00826-9"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00953-4"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015198"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.235"},{"key":"e_1_2_11_27_1","first-page":"1","volume-title":"SPRAVATO (Esketamine) Nasal Spray, CIII","author":"Janssen Pharmaceuticals, Inc","year":"2025"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00607095"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140251"},{"issue":"1","key":"e_1_2_11_30_1","first-page":"43","article-title":"Metabolic Capacity of Nasal Tissue Interspecies Comparisons of Xenobiotic\u2010Metabolizing Enzymes","volume":"380","author":"Thornton\u2010Manning J. R.","year":"1997","journal-title":"Mutation Research"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01116-3"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.07.008"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318218a881"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563279"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.3.270"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003529"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00699-4"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16010037"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab084"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"issue":"3","key":"e_1_2_11_41_1","article-title":"Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment\u2010Resistant Depression: Assessment of Long\u2010Term Safety in a Phase 3, Open\u2010Label Study (SUSTAIN\u20102)","volume":"81","author":"Wajs E.","year":"2020","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf027"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.10.018"},{"key":"e_1_2_11_45_1","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) \u201cSpravato: Assessment Report. EMA\/141382\/2021 \u201d1\u2013163."},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X291958"},{"issue":"3","key":"e_1_2_11_49_1","article-title":"Antidepressants Versus Placebo for Depression in Primary Care","volume":"2009","author":"Arroll B.","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"e_1_2_11_50_1","article-title":"Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double\u2010Blind, Randomized Study (ASPIRE I)","volume":"81","author":"Fu D. J.","year":"2020","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa068"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1317"},{"key":"e_1_2_11_53_1","first-page":"42","article-title":"Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive\u2010Controlled Study","volume":"65","author":"Kosik\u2010Gonzalez C.","year":"2025","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:24:41Z","timestamp":1777955081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/cts.70527"],"URL":"https:\/\/doi.org\/10.1111\/cts.70527","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70527"}}